| |
| |
|
| Insider
Information: |
Sanna Bastiano |
| Relationship: |
Director |
| City: |
Boston |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
37,938 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$13,553,699 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
37,938 |
|
|
| Total
Value |
$13,553,699 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Cell & Genetic Th... |
2023-05-08 |
32,038 |
2021-02-03 |
0 |
Premium* |
|
|
Adicet Bio, Inc |
ACET |
Director |
2023-06-01 |
5,900 |
2023-06-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
43 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic TherapiesO |
• – – |
2021-02-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,175 |
|
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-05-16 |
4 |
AS |
$250.56 |
$11,377 |
D/D |
(45) |
41,749 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-01-31 |
4 |
AS |
$325.00 |
$34,450 |
D/D |
(106) |
37,998 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2021-05-17 |
4 |
AS |
$215.95 |
$24,230 |
D/D |
(112) |
34,108 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-02-13 |
4 |
AS |
$300.39 |
$33,944 |
D/D |
(113) |
61,915 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-05-02 |
4 |
AS |
$255.47 |
$82,930 |
D/D |
(320) |
41,696 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-11-02 |
4 |
AS |
$310.10 |
$100,045 |
D/D |
(320) |
38,104 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-05-05 |
4 |
AS |
$350.03 |
$147,713 |
D/D |
(422) |
34,888 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-04-04 |
4 |
AS |
$314.22 |
$164,854 |
D/D |
(522) |
47,280 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-02-01 |
4 |
D |
$243.64 |
$128,155 |
D/D |
(526) |
55,992 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-04-07 |
4 |
AS |
$275.71 |
$154,935 |
D/D |
(561) |
42,782 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-04-04 |
4 |
AS |
$267.10 |
$150,452 |
D/D |
(562) |
46,506 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2021-04-30 |
4 |
D |
$217.21 |
$166,383 |
D/D |
(766) |
35,068 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2021-07-30 |
4 |
D |
$200.39 |
$153,499 |
D/D |
(766) |
33,342 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2021-11-01 |
4 |
D |
$185.07 |
$141,764 |
D/D |
(766) |
32,576 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-04-29 |
4 |
D |
$276.17 |
$211,546 |
D/D |
(766) |
42,016 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-08-01 |
4 |
D |
$276.62 |
$211,891 |
D/D |
(766) |
40,983 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-11-01 |
4 |
D |
$312.84 |
$240,261 |
D/D |
(768) |
38,424 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-02-10 |
4 |
D |
$294.33 |
$265,486 |
D/D |
(902) |
66,368 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2021-05-03 |
4 |
AS |
$218.06 |
$209,691 |
D/D |
(960) |
34,108 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-02-10 |
4 |
D |
$237.74 |
$232,747 |
D/D |
(979) |
53,973 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-02-02 |
4 |
AS |
$250.04 |
$261,017 |
D/D |
(1,040) |
54,952 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2021-02-10 |
4 |
D |
$214.16 |
$287,831 |
D/D |
(1,344) |
40,550 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2022-04-01 |
4 |
D |
$263.09 |
$353,593 |
D/D |
(1,344) |
47,068 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Cell & Genetic Therapies |
• – – |
2023-05-02 |
4 |
AS |
$350.32 |
$568,768 |
D/D |
(1,622) |
38,091 |
0 |
% |
|
43 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
